-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA approves Genentech Tecentriq-chemo combo for adjuvant stage III dMMR colon cancer

PUBT·10/09/2026 05:05:03
FDA approves Genentech Tecentriq-chemo combo for adjuvant stage III dMMR colon cancer
  • FDA cleared Genentech’s Tecentriq with fluoropyrimidine plus oxaliplatin for adjuvant treatment of stage III dMMR colon cancer.
  • Decision based on Phase III ATOMIC trial showing a 50% reduction in recurrence or death versus chemotherapy alone.
  • 36-month disease-free survival reached 86% with the regimen versus 76% for chemotherapy alone.
  • Marks Tecentriq’s 12th U.S. indication, expanding its footprint into post-surgery colon cancer treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genentech Inc. published the original content used to generate this news brief on October 08, 2026, and is solely responsible for the information contained therein.